Case 1:13-cv-05723-NLH-AMD Document 90-9 Filed 05/21/14 Page 1 of 5 PageID: 956
`
`
`
`
`EXHIBIT 9
`
`
`
`
`
`
`
`
`
`
`
`EKR Therapeutics, LLC Exhibit 2008 Page 1
`
`

`

`Case 1:13-cv-05723-NLH-AMD Document 90-9 Filed 05/21/14 Page 2 of 5 PageID: 957
`
`From: D'Amore, Matthew M. [mailto:MDAmore@mofo.com]
`Sent: Monday, May 19, 2014 2:03 PM
`To: Giove, Nicholas; Liu, Hui; Prutzman, Sarah L.; eabraham@hillwallack.com
`Cc: Haug, Ed; Chen, Angus; Clymer, Leann M.; Harkness, Michael W.; McShane, Sheila F.; MGriffinger@gibbonslaw.com;
`Doyle, David C.; Hackman, Blaine M.
`Subject: RE: Cornerstone v. Sandoz
` 
`Dear Nick: 
`
`  
`Thanks for your reply.  The stipulation we propose has been used in other ANDA cases, and we believe it is an effective 
`and efficient way to proceed because it obviates collateral motion practice and allows the case to proceed on the 
`merits.   
`
`  
`We understand your client’s interest in making sure it has sued the proper Sandoz entity, and confirm that Sandoz Inc. is 
`the proper defendant.  Plaintiffs’ cause of action under 271(e) is against the entity that “submit[s]” the ANDA; that is 
`Sandoz Inc.  Moreover, the relief Plaintiffs could obtain if successful in this action includes, for generic products not yet 
`approved, an injunction that “the effective date of any approval of the drug or veterinary biological product involved in 
`the infringement to be a date which is not earlier than the date of the expiration of the patent which has been 
`infringed”.  As Sandoz Inc. is the “submitter” of ANDA 203978, and any injunction awarded would apply to that ANDA 
`product, no other party is necessary to this action for Plaintiffs to secure the relief they seek.  In any event, the 
`stipulation we suggest would address your client’s concern that Sandoz AG abide by the judgment in this case. 
`
`  
`As to the discovery you request, the parties are in the process of document collection and production, and relevant, 
`responsive documents will be produced in due course subject to Sandoz Inc.’s objections and responses, and 
`agreements that may be reached among the parties.  Plaintiffs’ request for documents irrelevant to the merits of this 
`action should not be taken out of turn given that Plaintiffs have, for example, not yet produced the complete NDA for 
`their product despite our repeated requests.  But as noted, to the extent Plaintiffs have a concern that Sandoz AG 
`adhere to the judgment in this case, that would be addressed by the stipulation we propose. 
`
`  
`As to your request for the legal basis for Sandoz Inc.’s objection, we believe that the proposed amendments as untimely 
`and unnecessary.  As to Dobfar, they are too late – Plaintiffs knew of their role with respect to this matter since 
`November 2013, when Sandoz produced its ANDA.  As to Sandoz AG, they are unnecessary to the efficient disposition of 
`this action, especially in light of the stipulation we propose.  However, it is our hope that this matter may be resolved 
`without motion practice for the reasons set forth above, and we would be open to discussing this with you further. 
`
`  
`Regards, 
`–Matt. 
`
`  
`  
`
` 
`Matthew D'Amore 
`Morrison & Foerster LLP 
`250 West 55th Street | New York, NY 10019-9601 
`P: +1 (212) 468.8168 | F: +212.903 7820 
`mdamore@mofo.com | www.mofo.com 
`
`1
`
`EKR Therapeutics, LLC Exhibit 2008 Page 2
`
`

`

`Case 1:13-cv-05723-NLH-AMD Document 90-9 Filed 05/21/14 Page 3 of 5 PageID: 958
`
`From: Giove, Nicholas [mailto:NGiove@flhlaw.com]
`Sent: Friday, May 16, 2014 2:21 PM
`To: D'Amore, Matthew M.; Liu, Hui; Prutzman, Sarah L.; eabraham@hillwallack.com
`Cc: Haug, Ed; Chen, Angus; Clymer, Leann M.; Harkness, Michael W.; McShane, Sheila F.; MGriffinger@gibbonslaw.com;
`Doyle, David C.; Hackman, Blaine M.
`Subject: RE: Cornerstone v. Sandoz 
`
`  
`Matt: 
`
`  
`Your response to my May 6 email failed to confirm whether or not Sandoz Inc. consents to Plaintiffs’ proposed 
`amendment.  Please confirm by Monday that Sandoz Inc. consents to Plaintiffs’ motion for leave, or explain in detail 
`your legal/factual basis for Sandoz Inc. withholding consent.   
`
`  
`As I stated in my May 6 e‐mail, we intended to file our Amended Complaint this past week to minimize any disruptions 
`to the current case schedule.  Nevertheless, we are willing to briefly postpone our filing to consider your proposal made 
`on Sandoz AG’s behalf.  Your email suggests that “Sandoz Inc. is the ANDA holder.”  But the “Manufacturing and Supply 
`Agreement” between ACS Dobfar Info SA and Sandoz AG states that “SANDOZ [AG] is, and will remain, for the duration 
`of this Agreement, the sponsor and sole owner of the ANDA. . . .”  In order for us to consider your proposal, please 
`produce all documents concerning any communications or agreements between and among Sandoz AG, Sandoz Inc., 
`and ACS Dobfar Info SA relating to each entity’s ownership rights and/or responsibilities concerning ANDA No. 203978 
`and the products described therein. 
`
`  
`Regards, 
`Nick 
`  
`  
`--------------------------------------------------------- 
`Nicholas F. Giove 
`FROMMER LAWRENCE & HAUG LLP 
`745 Fifth Avenue 
`New York, NY 10151 
`
` 
`Phone: (212) 863-2607 
`Fax: (212) 588-0500 
`E-mail: NGiove@flhlaw.com 
`
`  
`From: D'Amore, Matthew M. [mailto:MDAmore@mofo.com]
`Sent: Friday, May 16, 2014 11:53 AM
`To: Giove, Nicholas; Liu, Hui; Prutzman, Sarah L.; eabraham@hillwallack.com
`Cc: Haug, Ed; Chen, Angus; Clymer, Leann M.; Harkness, Michael W.; McShane, Sheila F.; MGriffinger@gibbonslaw.com;
`Doyle, David C.
`Subject: RE: Cornerstone v. Sandoz 
` 
`
` Dear Nick: 
`We have advised Sandoz AG of Plaintiffs’ proposal to add them to this litigation. We do not see why
`Plaintiffs believe that is necessary, as Sandoz Inc. is the ANDA holder, nor why Plaintiffs believe they
`could get jurisdiction over a non‐resident defendant under recent Supreme Court precedent. 
`However, rather than engage those debates and the motion practice it may entail, Sandoz AG would be
`willing to enter into an agreement whereby it would provide discovery in the action, and agree to be
`bound by the outcome, in return for Plaintiffs agreement to refrain from naming them as a party to the
`case. If that approach is acceptable to Plaintiffs, please let us know, and we will provide an appropriate
`agreement. 
`Regards, 
`–Matt. 
`
`2
`
`EKR Therapeutics, LLC Exhibit 2008 Page 3
`
`

`

`
`
`
`Case 1:13-cv-05723-NLH-AMD Document 90-9 Filed 05/21/14 Page 4 of 5 PageID: 959
`
` 
`Matthew D'Amore 
`Morrison & Foerster LLP 
`250 West 55th Street | New York, NY 10019-9601 
`P: +1 (212) 468.8168 | F: +212.903 7820 
`mdamore@mofo.com | www.mofo.com 
` 
`From: Giove, Nicholas [mailto:NGiove@flhlaw.com]
`Sent: Tuesday, May 06, 2014 3:10 PM
`To: D'Amore, Matthew M.; Liu, Hui; Prutzman, Sarah L.; eabraham@hillwallack.com
`Cc: Haug, Ed; Chen, Angus; Clymer, Leann M.; Harkness, Michael W.; McShane, Sheila F.; MGriffinger@gibbonslaw.com
`Subject: Cornerstone v. Sandoz 
`  
`
` 
`
`Matt: 
`
`  
`Attached is a draft Amended Complaint that we intend to file in the next week.  Please confirm pursuant to Fed. R. Civ. 
`P. 15(a)(2) that Defendants consent to Plaintiffs amending their Complaint as set forth in the attached draft.  Please also 
`let us know if Defendants believe the Amended Complaint should be filed under seal. 
`
`  
`Regards, 
`Nick 
`  
`--------------------------------------------------------- 
`Nicholas F. Giove 
`FROMMER LAWRENCE & HAUG LLP 
`745 Fifth Avenue 
`New York, NY 10151 
`
` 
`Phone: (212) 863-2607 
`Fax: (212) 588-0500 
`E-mail: NGiove@flhlaw.com 
`  
`  
`
`This message originates from the law firm of Frommer Lawrence & Haug LLP. It contains information that may be confidential or privileged and is intended only for
`the individual or entity named above. No one else may disclose, copy, distribute, or use the contents of this message. Unauthorized use, dissemination, and
`duplication is strictly proh bited, and may be unlawful. All personal messages express views solely of the sender, which are not to be attributed to Frommer
`Lawrence & Haug LLP, and may not be copied or distributed without this disclaimer. If you receive this message in error, please notify us immediately at
`firm@flhlaw.com or call (212) 588-0800.  
`
`
`To ensure compliance with requirements imposed by the IRS, Morrison & Foerster LLP informs you that, if any
`advice concerning one or more U.S. Federal tax issues is contained in this communication (including any
`attachments), such advice is not intended or written to be used, and cannot be used, for the purpose of (i)
`avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another
`party any transaction or matter addressed herein.
`
`For information about this legend, go to http://www.mofo.com/Circular230/
`
`============================================================================
`
`
`3
`
`EKR Therapeutics, LLC Exhibit 2008 Page 4
`
`

`

`Case 1:13-cv-05723-NLH-AMD Document 90-9 Filed 05/21/14 Page 5 of 5 PageID: 960
`This message contains information which may be confidential and privileged. Unless you are the addressee (or
`authorized to receive for the addressee), you may not use, copy or disclose to anyone the message or any
`information contained in the message. If you have received the message in error, please advise the sender by
`reply e-mail MDAmore@mofo.com, and delete the message. 
`
`To ensure compliance with requirements imposed by the IRS, Morrison & Foerster LLP informs you that, if any
`advice concerning one or more U.S. Federal tax issues is contained in this communication (including any
`attachments), such advice is not intended or written to be used, and cannot be used, for the purpose of (i)
`avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another
`party any transaction or matter addressed herein.
`
`For information about this legend, go to http://www.mofo.com/Circular230/
`
`============================================================================
`
`This message contains information which may be confidential and privileged. Unless you are the addressee (or
`authorized to receive for the addressee), you may not use, copy or disclose to anyone the message or any
`information contained in the message. If you have received the message in error, please advise the sender by
`reply e-mail MDAmore@mofo.com, and delete the message.
`
`4
`
`EKR Therapeutics, LLC Exhibit 2008 Page 5
`
`